Latest news and press releases about GT Biopharma, Inc. (GTBP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells.
Price
| Price | $7.81 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.40 |
| EV / EBITDA | -0.48 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -443.08% |
| Return on Invested Capital | -457.75% |
| Return on Assets | -381.53% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARTL · CARM · DRMA · LIPO · PBM · PTIX · REVB
Explore sector: Healthcare · Biotechnology
More sections of GTBP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks